On November 25, 1901, Auguste D. Alzheimer’s now famous first case was admitted to a hospital in Frankfurt. Her presenting problem wasn’t cognitive deficit but a cluster of psychiatric symptoms that included unpredictable and challenging behavior, auditory hallucinations, and paranoia. Over the following century, psychiatrists and neurologists with an interest in Alzheimer’s disease somehow fostered a preoccupation with the neuropathology, neurochemistry, and molecular biology of impaired cognition that pushed study of the more psychological and psychopathological aspects of the disorder into the background. Most recently, the advent of the cholinesterase inhibitors has led to an unfortunate increase in the categorization of individuals with dementia in terms of their Mini-Mental State Examination (MMSE) score. For example, in the United Kingdom, access to these drugs is currently rationed on the basis of "guidance" from a government body that recommends stopping prescription when the MMSE score drops below 12.